JOHN SHIPP: Open Payments
NPI 1801027453 · GILBERT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 35 payments from 13 companies in 2025. Trend: 2023 $759 · 2024 $701 · 2025 $693
Food & beverage: $693
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $158 |
| Astellas Pharma US Inc | 4 | $87 |
| ABBVIE INC. | 5 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Optinose US, Inc. | 3 | $56 |
| Abbott Laboratories | 3 | $54 |
| Novo Nordisk Inc | 2 | $49 |
| Lilly USA, LLC | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
Products named: AIRSUPRA, Veozah, CAPLYTA, QULIPTA, Xhance, FREESTYLE LIBRE 3, MOUNJARO, FARXIGA.
Industry payments across AZ — which companies pay providers there.
